Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKAG1 | P54619 | 3/20 | 0.41 |
| ▸ | PRKAA2 | P54646 | 3/20 | 0.41 |
| ▸ | PRKAB1 | Q9Y478 | 3/20 | 0.41 |
| ▸ | F3 | P13726 | 6/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.39 |
| ▸ | TYR | P14679 | 1/20 | 0.39 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | TOP1 | P11387 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18815980 | 1.00 | PRKAG1 (0.41) | PRKAG1PRKAA2PRKAB1F3PTPN1 | |
| SCHEMBL30842605 | 0.97 | PRKAG1 (0.39) | PRKAG1PRKAA2PRKAB1F3PTPN1 | |
| SCHEMBL18818094 | 0.97 | PRKAG1 (0.39) | PRKAG1PRKAA2PRKAB1F3PTPN1 | |
| SCHEMBL18817848 | 0.97 | PRKAG1 (0.39) | PRKAG1PRKAA2PRKAB1F3PTPN1 | |
| 11-Oxomogroside Iv A SCHEMBL23685849 | 0.97 | PRKAG1 (0.39) | PRKAG1PRKAA2PRKAB1F3PTPN1 | |
| SCHEMBL23685972 | 0.97 | PRKAG1 (0.39) | PRKAG1PRKAA2PRKAB1F3PTPN1 | |
| 11-Oxomogroside Iv A SCHEMBL18817849 | 0.97 | PRKAG1 (0.39) | PRKAG1PRKAA2PRKAB1F3PTPN1 | |
| SCHEMBL18805157 | 0.97 | PRKAG1 (0.39) | PRKAG1PRKAA2PRKAB1F3PTPN1 | |
| 11-Oxomogroside Iv A SCHEMBL29378868 | 0.97 | PRKAG1 (0.39) | PRKAG1PRKAA2PRKAB1F3PTPN1 | |
| 11-Oxomogroside Iv A SCHEMBL26324816 | 0.97 | PRKAG1 (0.39) | PRKAG1PRKAA2PRKAB1F3PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119365085-A | Contains buna precious sweet protein composition | 奇华顿股份有限公司 | 2025-01-24 | — | — | CN | claimed |
| US-20240114930-A1 | COMPOSITIONS AND METHODS FOR TASTE MODULATION | GIVAUDAN SA (CH) | 2024-04-11 | — | — | US | claimed |
| EP-4333641-A1 | BEVERAGES COMPRISING SALTS WITH IMPROVED TASTE | The Coca-Cola Company (US) | 2024-03-13 | — | — | EP | claimed |
| CN-117545364-A | Sweetener and flavor compositions prepared from glycosylated mogrosides or momordica grosvenori extracts, methods of making and using the same | 伊比西(北京)植物药物技术有限公司 | 2024-02-09 | — | — | CN | claimed |
| US-20240000113-A1 | COMPOSITIONS AND METHODS FOR TASTE MODULATION | GIVAUDAN SA (CH) | 2024-01-04 | — | — | US | claimed |
| WO-2022235772-A1 | BEVERAGES COMPRISING SALTS WITH IMPROVED TASTE | THE COCA-COLA COMPANY (US) | 2022-11-10 | — | — | WO | claimed |
| EP-4704601-A1 | DAIRY-ALTERNATIVE BEVERAGES WITH IMPROVED TASTE | The Coca-Cola Company (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-4704600-A1 | DAIRY BEVERAGES WITH IMPROVED TASTE | The Coca-Cola Company (US) | 2026-03-11 | — | — | EP | disclosed |
| US-12532901-B2 | Compositions and methods for taste modulation | GIVAUDAN SA (CH) | 2026-01-27 | — | — | US | disclosed |
| US-12532902-B2 | Compositions and methods for taste modulation | GIVAUDAN SA (CH) | 2026-01-27 | — | — | US | disclosed |
| EP-4658090-A1 | SIAMENOSIDE I SWEETENED BEVERAGES WITH MOGROSIDE BLENDS | The Coca-Cola Company (US) | 2025-12-10 | — | — | EP | disclosed |
| WO-2025207298-A1 | MOGROSIDE COMPOSITIONS AND METHODS OF PRODUCING SAME | ELO LIFE SYSTEMS (US) | 2025-10-02 | — | — | WO | disclosed |
| US-20250290110-A1 | MOGROSIDE COMPOSITIONS AND METHODS OF PRODUCING SAME | ELO LIFE SYSTEMS | 2025-09-18 | — | — | US | disclosed |
| US-20230389588-A1 | COMPOSITIONS AND METHODS FOR TASTE MODULATION | GIVAUDAN SA (CH) | 2023-12-07 | — | — | US | disclosed |
| WO-2023215812-A1 | TEA BEVERAGES WITH IMPROVED TASTE | THE COCA-COLA COMPANY (US) | 2023-11-09 | — | — | WO | disclosed |
| WO-2023034928-A1 | METHODS AND COMPOSITIONS COMPRISING CAFFEINE AND/OR A DERIVATIVE THEREOF AND A POLYPHENOL | THE COCA-COLA COMPANY (US) | 2023-03-09 | — | — | WO | disclosed |
| EP-4138572-A1 | BEVERAGES COMPRISING SIAMENOSIDE I WITH ENHANCED FLAVOR | The Coca-Cola Company (US) | 2023-03-01 | — | — | EP | disclosed |
| EP-4114190-A1 | FAT FREE, NON-DAIRY SOFT SERVE COMPOSITIONS | The Coca-Cola Company (US) | 2023-01-11 | — | — | EP | disclosed |
| WO-2022251624-A1 | AMINO ACID HYDRATION FORMULATION AND METHOD OF USE | THE COCA-COLA COMPANY (US) | 2022-12-01 | — | — | WO | disclosed |
| EP-4017282-A1 | STABLE CREATINE BEVERAGES | The Coca-Cola Company (US) | 2022-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12532901-B2 | Compositions and methods for taste modulation | TAS2R60, TAS2R30, TAS2R50 | PRKAG1 2408/4885PRKAA2 2632/4885PRKAB1 2090/4885 |
| US-12532902-B2 | Compositions and methods for taste modulation | TAS2R60, TAS2R30, TAS2R40 | PRKAG1 2610/4885PRKAA2 2443/4885PRKAB1 2494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.